SWOG clinical trial number
SWOG-9026
A Phase I, Open Label, Multicenter Study of the Safety, Tolerability and Biological Effects of SDZ ILE 964 (Recombinant Human Interleukin-3), Administered to Patients with Metastatic Cancer Prior to and After Receiving a Carboplatin/Etoposide Chemotherapy Regimen
Closed
Phase
Accrual
100%
Published
Abbreviated Title
A Phase I, Open Label, Multicenter Study of the Safety, Tolerability and Biological Effects of SDZ ILE 964 (Recombinant Human Interleukin-3), Administered to Patients with Metastatic Cancer Prior to…
Activated
07/15/1991
Closed
09/29/1992
Publication Information Expand/Collapse
1995
Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: A Southwest Oncology Group study.
1992
Phase I trial of IL-3, carboplatin and etoposide in patients with solid tumors: Southwest Oncology Group study (SWOG) 9026.